Tier 1 — highest

Effect of Nutritional Supplements for Reducing Homocysteine Levels in Healthy Adults: A Systematic Review and Network Meta-Analysis of Randomized Trials

Cai Liu, Hui Yao, Fang Wang
Nutrition reviews 2025 83(7):e1533-e1543

Bibliography

PubMed
PMID 39960689
PubMed Central
PMC12166197
DOI
10.1093/nutrit/nuae191
Funding
Reported funding/support: The Science Foundation of Lanzhou University Second Hospital YJS-BD-19 FundingThis work was supported by The Science Foundation of Lanzhou University Second Hospital (grant YJS-BD-19).
Competing interests
Reported disclosure: The authors declare there is no conflict of any relevant interests.

Study snapshot

DesignNetwork meta-analysis of RCTs
ModelEvidence synthesis; mixed research models
Sample16 studies of homocysteine-lowering supplements
InterventionFolic acid and other nutrient regimens across doses
DurationSearch through July 2023
EndpointsHomocysteine; Supplement comparisons

What the study showed, in plain terms

Published in 2025, this source examined safety assessments and evidence synthesis. Its evidence base was 16 studies of homocysteine-lowering supplements. It evaluated Folic acid and other nutrient regimens across doses across Search through July 2023.

Folate-containing combinations ranked highly for homocysteine lowering, illustrating that methylation support is not unique to betaine.

Network rankings include indirect comparisons and sparse treatment nodes. They do not prove that TMG prevents clinical disease or is required with NMN.

Continue with TMG Data Center

Continue with TMG and Homocysteine: How Much Can Betaine Lower It?

Key findings

  • Folate-containing combinations ranked highly for homocysteine lowering, illustrating that methylation support is not unique to betaine.
  • The recorded outcome domains were Homocysteine; Supplement comparisons.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Network rankings include indirect comparisons and sparse treatment nodes. They do not prove that TMG prevents clinical disease or is required with NMN.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Accessible full-text extract plus indexed bibliographic data. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 1
Effects of betaine supplementation on cardiovascular markers: A systematic review and Meta-analysis
Damoon Ashtary-Larky et al. · Critical reviews in food science and nutrition · 2022
Tier 1
Betaine Supplementation Moderately Increases Total Cholesterol Levels: A Systematic Review and Meta-Analysis
Emilia E Zawieja et al. · Journal of dietary supplements · 2021
Tier 2
Safety of betaine as a novel food pursuant to Regulation (EC) No 258/97
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) et al. · EFSA journal. European Food Safety Authority · 2017
Tier 2
Safety of betaine as a novel food pursuant to Regulation (EU) 2015/2283
EFSA Panel on Nutrition, Novel Foods and Food Allergens (EFSA NDA Panel) et al. · EFSA journal. European Food Safety Authority · 2019
Tier 4
Postauthorization safety study of betaine anhydrous
Ulrike Mütze et al. · Journal of inherited metabolic disease · 2022

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology